{"commentary":{"count":20,"free_build_floor":8,"listing_floor":3,"by_channel":{"podcast":11,"x_thread":5,"youtube":4},"note":"Indexed podcasts, YouTube videos and X posts that name this trial. A report screens them, searches for more and cites what clinicians said when it is built."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT00052299\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's public preview; the full report is still bought."},"name":"AML-17","nct_id":"NCT00052299","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=aml-17-nct00052299. The price is fixed at order. We build the report after the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1250,"size":"standard","size_rule":"Standard: 13–40 commentary sources"},"registry":{"acronym":"AML-17","arms":[{"description":"GO + MICE for remission induction followed by GO + mini-ICE for consolidation","label":"ARM A","type":"EXPERIMENTAL"},{"description":"MICE for remission induction followed by mini-ICE for consolidation","label":"ARM B","type":"ACTIVE_COMPARATOR"}],"collaborators":["Gruppo Italiano Malattie EMatologiche dell'Adulto"],"completion_date":{"date":"2012-02","type":"ACTUAL"},"conditions":["Leukemia"],"enrollment":{"count":472,"type":"ACTUAL"},"has_results":false,"interventions":[{"name":"cytarabine","type":"DRUG"},{"name":"etoposide","type":"DRUG"},{"name":"gemtuzumab ozogamicin","type":"DRUG"},{"name":"idarubicin","type":"DRUG"},{"name":"mitoxantrone hydrochloride","type":"DRUG"}],"last_update":"2012-08-27","lead_sponsor":"European Organisation for Research and Treatment of Cancer - EORTC","official_title":"Gemtuzumab Ozogamicin (GO) Combined With Standard Intensive Chemotherapy Versus Standard Intensive Chemotherapy Alone For Induction/Consolidation In Patients 61-75 Years Old With Previously Untreated AML: A Randomized Phase III Trial (AML-17) Of The EORTC-LG and the GIMEMA-ALWP","overall_status":"COMPLETED","phases":["PHASE3"],"primary_completion_date":{"date":"2008-01","type":"ACTUAL"},"primary_outcomes":[{"measure":"Overall survival","timeFrame":null}],"references":[{"citation":"Amadori S, Suciu S, Stasi R, Salih HR, Selleslag D, Muus P, De Fabritiis P, Venditti A, Ho AD, Lubbert M, Thomas X, Latagliata R, Halkes CJ, Falzetti F, Magro D, Guimaraes JE, Berneman Z, Specchia G, Karrasch M, Fazi P, Vignetti M, Willemze R, de Witte T, Marie JP. Sequential combination of gemtuzumab ozogamicin and standard chemotherapy in older patients with newly diagnosed acute myeloid leukemia: results of a randomized phase III trial by the EORTC and GIMEMA consortium (AML-17). J Clin Oncol. 2013 Dec 10;31(35):4424-30. doi: 10.1200/JCO.2013.49.0771. Epub 2013 Oct 14.","pmid":"24127442","type":"DERIVED"}],"start_date":{"date":"2002-09"},"study_type":"INTERVENTIONAL","title":"Chemotherapy With or Without Gemtuzumab Ozogamicin in Treating Older Patients With Acute Myeloid Leukemia","url":"https://clinicaltrials.gov/study/NCT00052299"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"2.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/aml-17-nct00052299"}